Differential permeability of a human brain tumor xenograft in the nude rat: Impact of tumor size and method of administration on optimizing delivery of biologically diverse agents

Edward Neuwelt, Peggy A. Barnett, Christopher I. McCormick, Laura G. Remsen, Robert A. Kroll, Gary Sexton

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

To assess how to maximize drug delivery to intracerebral tumors and surrounding brain, this study examined the effects of route and method of administration and tumor size on the distribution of three agents in a nude rat intracerebral tumor xenograft model. Aminoisobutyric acid (M(r) 103), methotrexate (M(r) 454), and dextran 70 (M(r) 70,000) were administered i.v. or intra-arterially (i.a.) with or without osmotic blood-brain barrier disruption (BBBD) at 8, 12, or 16 days after tumor cell inoculation (n = 72). A 2.2- to 2.5-fold increase in delivery to tumor and surrounding brain was observed when i.a. was compared with i.v., and a 2.5- to 7.6-fold increase was observed when BBBD was compared with the saline control. The combined effect of i.a. administration and BBBD was to increase delivery 6.3-16.7- fold. The greatest benefit of BBBD was seen in animals with 8-day tumors, whereas BBBD had less benefit in improving delivery to intracerebral tumor and brain around tumor as the tumors grew larger. Regional delivery decreased as the molecular weight of the agent increased. Based on these results, we suggest that i.a. administration of antitumor agents may be adequate to obtain initial responses in large, very permeable, intracerebral tumors. However, in smaller, less permeable tumors or after an initial response to treatment, there may be a significant therapeutic advantage to i.a. agent administration and BBBD.

Original languageEnglish (US)
Pages (from-to)1549-1555
Number of pages7
JournalClinical Cancer Research
Volume4
Issue number6
StatePublished - Jun 1998

Fingerprint

Nude Rats
Heterografts
Brain Neoplasms
Permeability
Blood-Brain Barrier
Neoplasms
Aminoisobutyric Acids
Dextrans
Methotrexate
Antineoplastic Agents
Molecular Weight

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Differential permeability of a human brain tumor xenograft in the nude rat : Impact of tumor size and method of administration on optimizing delivery of biologically diverse agents. / Neuwelt, Edward; Barnett, Peggy A.; McCormick, Christopher I.; Remsen, Laura G.; Kroll, Robert A.; Sexton, Gary.

In: Clinical Cancer Research, Vol. 4, No. 6, 06.1998, p. 1549-1555.

Research output: Contribution to journalArticle

Neuwelt, Edward ; Barnett, Peggy A. ; McCormick, Christopher I. ; Remsen, Laura G. ; Kroll, Robert A. ; Sexton, Gary. / Differential permeability of a human brain tumor xenograft in the nude rat : Impact of tumor size and method of administration on optimizing delivery of biologically diverse agents. In: Clinical Cancer Research. 1998 ; Vol. 4, No. 6. pp. 1549-1555.
@article{5de6f6b8a69c43cea674c392174e10a5,
title = "Differential permeability of a human brain tumor xenograft in the nude rat: Impact of tumor size and method of administration on optimizing delivery of biologically diverse agents",
abstract = "To assess how to maximize drug delivery to intracerebral tumors and surrounding brain, this study examined the effects of route and method of administration and tumor size on the distribution of three agents in a nude rat intracerebral tumor xenograft model. Aminoisobutyric acid (M(r) 103), methotrexate (M(r) 454), and dextran 70 (M(r) 70,000) were administered i.v. or intra-arterially (i.a.) with or without osmotic blood-brain barrier disruption (BBBD) at 8, 12, or 16 days after tumor cell inoculation (n = 72). A 2.2- to 2.5-fold increase in delivery to tumor and surrounding brain was observed when i.a. was compared with i.v., and a 2.5- to 7.6-fold increase was observed when BBBD was compared with the saline control. The combined effect of i.a. administration and BBBD was to increase delivery 6.3-16.7- fold. The greatest benefit of BBBD was seen in animals with 8-day tumors, whereas BBBD had less benefit in improving delivery to intracerebral tumor and brain around tumor as the tumors grew larger. Regional delivery decreased as the molecular weight of the agent increased. Based on these results, we suggest that i.a. administration of antitumor agents may be adequate to obtain initial responses in large, very permeable, intracerebral tumors. However, in smaller, less permeable tumors or after an initial response to treatment, there may be a significant therapeutic advantage to i.a. agent administration and BBBD.",
author = "Edward Neuwelt and Barnett, {Peggy A.} and McCormick, {Christopher I.} and Remsen, {Laura G.} and Kroll, {Robert A.} and Gary Sexton",
year = "1998",
month = "6",
language = "English (US)",
volume = "4",
pages = "1549--1555",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "6",

}

TY - JOUR

T1 - Differential permeability of a human brain tumor xenograft in the nude rat

T2 - Impact of tumor size and method of administration on optimizing delivery of biologically diverse agents

AU - Neuwelt, Edward

AU - Barnett, Peggy A.

AU - McCormick, Christopher I.

AU - Remsen, Laura G.

AU - Kroll, Robert A.

AU - Sexton, Gary

PY - 1998/6

Y1 - 1998/6

N2 - To assess how to maximize drug delivery to intracerebral tumors and surrounding brain, this study examined the effects of route and method of administration and tumor size on the distribution of three agents in a nude rat intracerebral tumor xenograft model. Aminoisobutyric acid (M(r) 103), methotrexate (M(r) 454), and dextran 70 (M(r) 70,000) were administered i.v. or intra-arterially (i.a.) with or without osmotic blood-brain barrier disruption (BBBD) at 8, 12, or 16 days after tumor cell inoculation (n = 72). A 2.2- to 2.5-fold increase in delivery to tumor and surrounding brain was observed when i.a. was compared with i.v., and a 2.5- to 7.6-fold increase was observed when BBBD was compared with the saline control. The combined effect of i.a. administration and BBBD was to increase delivery 6.3-16.7- fold. The greatest benefit of BBBD was seen in animals with 8-day tumors, whereas BBBD had less benefit in improving delivery to intracerebral tumor and brain around tumor as the tumors grew larger. Regional delivery decreased as the molecular weight of the agent increased. Based on these results, we suggest that i.a. administration of antitumor agents may be adequate to obtain initial responses in large, very permeable, intracerebral tumors. However, in smaller, less permeable tumors or after an initial response to treatment, there may be a significant therapeutic advantage to i.a. agent administration and BBBD.

AB - To assess how to maximize drug delivery to intracerebral tumors and surrounding brain, this study examined the effects of route and method of administration and tumor size on the distribution of three agents in a nude rat intracerebral tumor xenograft model. Aminoisobutyric acid (M(r) 103), methotrexate (M(r) 454), and dextran 70 (M(r) 70,000) were administered i.v. or intra-arterially (i.a.) with or without osmotic blood-brain barrier disruption (BBBD) at 8, 12, or 16 days after tumor cell inoculation (n = 72). A 2.2- to 2.5-fold increase in delivery to tumor and surrounding brain was observed when i.a. was compared with i.v., and a 2.5- to 7.6-fold increase was observed when BBBD was compared with the saline control. The combined effect of i.a. administration and BBBD was to increase delivery 6.3-16.7- fold. The greatest benefit of BBBD was seen in animals with 8-day tumors, whereas BBBD had less benefit in improving delivery to intracerebral tumor and brain around tumor as the tumors grew larger. Regional delivery decreased as the molecular weight of the agent increased. Based on these results, we suggest that i.a. administration of antitumor agents may be adequate to obtain initial responses in large, very permeable, intracerebral tumors. However, in smaller, less permeable tumors or after an initial response to treatment, there may be a significant therapeutic advantage to i.a. agent administration and BBBD.

UR - http://www.scopus.com/inward/record.url?scp=0031749973&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031749973&partnerID=8YFLogxK

M3 - Article

C2 - 9626476

AN - SCOPUS:0031749973

VL - 4

SP - 1549

EP - 1555

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 6

ER -